Cumberland Partners Ltd Increases Position in Royalty Pharma PLC $RPRX

Cumberland Partners Ltd lifted its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 42.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,000 shares of the biopharmaceutical company’s stock after acquiring an additional 15,000 shares during the period. Cumberland Partners Ltd’s holdings in Royalty Pharma were worth $2,398,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of RPRX. LM Advisors LLC acquired a new stake in Royalty Pharma in the 4th quarter valued at $26,000. Lloyd Advisory Services LLC. acquired a new position in Royalty Pharma during the 4th quarter worth approximately $30,000. Private Trust Co. NA raised its stake in shares of Royalty Pharma by 52.9% during the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 288 shares during the period. Blue Trust Inc. raised its stake in shares of Royalty Pharma by 173.4% during the first quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 437 shares during the period. Finally, CIBC Private Wealth Group LLC lifted its position in shares of Royalty Pharma by 66.4% during the fourth quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 446 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Insiders Place Their Bets

In other news, Director Gregory Norden sold 3,045 shares of the firm’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $53.00, for a total transaction of $161,385.00. Following the transaction, the director directly owned 191,803 shares of the company’s stock, valued at approximately $10,165,559. This trade represents a 1.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 150,000 shares of the company’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $54.40, for a total transaction of $8,160,000.00. Following the completion of the sale, the executive vice president directly owned 559,399 shares of the company’s stock, valued at $30,431,305.60. The trade was a 21.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 427,800 shares of company stock worth $23,333,723. 18.84% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. UBS Group upped their price target on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, April 21st. TD Cowen boosted their price target on Royalty Pharma from $50.00 to $65.00 and gave the company a “buy” rating in a report on Monday, July 13th. Wall Street Zen upgraded shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Weiss Ratings downgraded shares of Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 15th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Seven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $56.57.

Royalty Pharma Price Performance

Shares of RPRX opened at $58.83 on Friday. Royalty Pharma PLC has a 12 month low of $34.08 and a 12 month high of $59.72. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.66 and a quick ratio of 2.66. The stock has a fifty day moving average price of $55.60 and a 200 day moving average price of $49.21. The company has a market cap of $33.88 billion, a P/E ratio of 40.02, a PEG ratio of 10.45 and a beta of 0.43.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The company had revenue of $630.58 million during the quarter, compared to the consensus estimate of $881.69 million. On average, research analysts forecast that Royalty Pharma PLC will post 5.18 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a dividend of $0.235 per share. This represents a $0.94 dividend on an annualized basis and a yield of 1.6%. The ex-dividend date is Friday, August 14th. Royalty Pharma’s payout ratio is 63.95%.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.